Evidence mapPaperPMID 42428571Full record

ReviewFrontiers in chemistry2026

AI-driven drug reposition for pathogens: a new paradigm in pandemic preparedness.

Lixuan Ma, Jingshu Zhao, Junwen Luan, Leiliang Zhang

Abstract readReview
In one paragraph

Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lixuan MaDepartment of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Jingshu ZhaoDepartment of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Junwen LuanDepartment of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Leiliang ZhangDepartment of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Faced with a severe outbreak of diseases caused by newly emerging and recurrent pathogens, the development cycle of traditional drugs is long, making it difficult to meet emergency needs. Drug repositioning has become a key strategy for rapidly providing therapies by exploring new therapeutic uses of approved drugs. However, traditional reposition methods have bottlenecks such as slow speed and strong randomness. Artificial intelligence (AI) is revolutionizing drug reposition by analyzing and integrating multi-source data with computational models, dramatically accelerating the discovery process. This article summarizes the core technological approaches of AI-driven drug reposition, including predictions based on network medicine, virtual screening through deep learning models, and association discovery via real-world data mining. Multiple successful cases are presented to verify their effectiveness. Although there are still challenges in terms of data quality, model interpretability, and clinical translation, AI will undoubtedly reshape our drug development paradigm for addressing future public health crises, serving as a pivotal engine for rapid response and precise intervention.

Indexed as

AI-drivenalphafold 3 (AF3)deep integrated network analysis (DINA)drug repositioninginfectious diseases

Identifiers

PMID42428571
PMCPMC13345848

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.